BNET Industries
Market Cap:$145.8B
Last Fiscal Year Sales:$48.4B
- Public
- US
Dow Jones Description
Taking care of you and your four-legged friends too! Pfizer Inc. (NYSE: PFE), based in New York, NY, discovers, develops, manufactures and sells prescription medications for humans and animals. Employing about 115,000 people, this $51.3 billion company operates in three segments: Human Health, Consumer Healthcare and Animal Health. Together, these segments cover treatments for diseases such as cardiovascular and metabolic diseases, medications for oral care, tobacco dependence, and products for prevention and treatment of diseases in livestock and pets.
Number of Employees 81,800
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Pfizer PFE and Crown Bio to Collaborate in Development of Novel Therapeutics for Asian Cancers
-
Research and Markets: The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to...
-
Science and Technology: Pfizer to buy Croatian drug patent
-
Bristol-Myers Squibb Raises Exchange Offer Price For Mead Johnson Shares - Update
-
'IT boosts efficiency & innovation'
-
Inspector General Saved Billions in Healthcare This Year
-
Pfizer and B.C. launch $9M collaboration to tackle cancer
-
Reportlinker Adds Growth Factors Blood And Tissue - A World Report
-
Protalix Completes NDA Submission for taliglucerase alfa for the Treatment of Gaucher s Disease
-
Pfizer Inc. PFE JOBS Acquires Rights to Protalix Biotherapeutics's Gaucher Drug in Deal Worth $115M
-
Conservationists salute two corporations
-
Pfizer PFE Will Not Renew Ethical Distribution Agreement Term with MWI Veterinary Supply MWIV
-
2009: The Year That Was For Pfizer
-
A 2nd Loss for Pfizer in Drug Suits
-
Pfizer acquires stem cell therapies assets of Axordia
-
Standpoint Raised Its FY10 Price Target on Pfizer PFE to $24
-
ImmunoVaccine signs exclusive licence deal with Pfizer
-
Pfizer Animal Health selects Bader Rutter as agency of record
News & Analysis
Filter by
lipitor and pfizer inc. - All News and Analysis
Pfizer Inc. Q3 2008 Earnings Conference Call Transcript
Seeking Alpha
- 2008-10-21
Question-and-Answer Session[Operator Instructions]. Sir, our first question comes from David Risinger of Merrill Lynch. Please proceed with your question. David Risinger - Merrill Lynch Thanks very much. I have two questions. The first is related to Lipitor. On the Lipitor sales, where sales impacted in 2008 or in 2007...
Pfizer Cuts a Deal -- No Bid for Ranbaxy
BNET
- 2008-06-18
So Pfizer apparently won't be playing the spoiler in the Daiichi-Ranbaxy merger after all. Instead, CEO Jeff Kindler cut a deal with the Indian generics maker that will delay the introduction of generic Lipitor by about 20 months. Ranbaxy is now spared the cost and uncertainty involved...
U.S. Patent and Trademark Office to Confirm Patentability of Lipitor Basic Patent
- 2008-04-30
NEW YORK -- Pfizer Inc announced today that the U.S. Patent & Trademark Office has issued a communication notifying the company that it will confirm the patentability of the claims of Pfizer's '893 basic patent for Lipitor. The Patent Office had conducted a re-examination of the '893 patent in response...
Spanish Appellate Court Rules in Pfizer's Favor, Upholds Lipitor Patent
- 2008-03-31
NEW YORK -- Pfizer Inc said today that the Court of Appeal of Barcelona has upheld the company's enantiomer patent covering the calcium salt of atorvastatin, the active ingredient in Lipitor, reversing the lower court decision. The enantiomer patent expires in July 2010.
Pfizer Receives Initial Communication from U.S. Patent and Trademark Office Regarding Lipitor Basic Patent
- 2008-01-14
NEW YORK -- Pfizer Inc announced today that the U.S. Patent & Trademark Office has issued its first communication in the reexamination of the '893 basic patent for Lipitor, initially rejecting the patent's claims. This initial action, which is how the Office raises its issues with the patentee, will now...
Pfizer to Appeal German Court Decision in Lipitor Patent Case; Company Notes That Ruling Has No Immediate Commercial Impact
- 2007-10-29
NEW YORK -- Pfizer Inc said today that the Federal Patent Court in Munich, Germany has revoked the company's patent covering atorvastatin calcium, the active ingredient in Lipitor. The patent at issue in the lawsuit (EP 409,281) expires in July 2010.
Ranbaxy loses battle for Lipitor patent in Canada.
- 2007-09-14
Sep. 14--NEW DELHI -- In a setback for Ranbaxy in its global battle over the patent of Lipitor, a Canadian federal court has ruled that the company's generic drug Atorvastatin infringes upon one of Pfizer's Lipitor patent. However, the court dismisse Sep. 14--NEW DELHI -- In...
Pfizer Proves It Can Do More with Lipitor - Protecting Vital Access to Patients at the Heart of Winning Managed Care Strategy
- 2007-08-30
FEASTERVILLE, Pa. -- With Lipitor's formulary access constricting due to generic competition and looming patent expiration, Pfizer aims to extend the health of its flagship cholesterol reducer with an aggressive promotional regimen rivaling that of a new drug in its launch phase. During the first half of 2007 Lipitor was...
High Court in Dublin Rules in Pfizer's Favor in Patent Case, Lipitor Protected from Generic Competition until 2011
- 2007-07-10
NEW YORK -- Pfizer Inc said today that the High Court in Dublin, Ireland has ruled that the basic patent covering atorvastatin - the active ingredient in Lipitor - would be infringed by a competitor product from generics manufacturer Ranbaxy. The decision, which is subject to a possible appeal, prevents...
PFIZER INC - Research Update.
- 2007-03-07
Lipitor Receives FDA Approval for Five New Indications in Patients With Heart Disease ...
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
Presented by the Premiere Rewards Gold Card from American Express